Once You Reach The Intensive Care Unit, It's Too Late for Sucess With the HCQ

NUKE PRO: Exposing Truth Anti-Nuclear Information and Resources, and Disaster Preparation Planning: http://nukeprofessional.blogspot.com/

 This was an early Summer cited reason to bad mouth HCQ as ineffective.     But it was too little too late. 

The “plan” was always the Vaccine.   And to release the vaccine under emergency authorization, it required by law that there be no “treatment”. 

And that is why all treatments were brutally attacked or just ignored.   Because they needed to release the vaccine. 

And look at the hundreds of “Authors”, its just plain weird.

https://pubmed.ncbi.nlm.nih.gov/33165621/

—————————————————-

Results: Among 479 patients who were randomized (median age, 57 years; 44.3% female; 37.2% Hispanic/Latinx; 23.4% Black; 20.1% in the intensive care unit; 46.8% receiving supplemental oxygen without positive pressure; 11.5% receiving noninvasive ventilation or nasal high-flow oxygen; and 6.7% receiving invasive mechanical ventilation or extracorporeal membrane oxygenation), 433 (90.4%) completed the primary outcome assessment at 14 days and the remainder had clinical status imputed. The median duration of symptoms prior to randomization was 5 days (interquartile range [IQR], 3 to 7 days). Clinical status on the ordinal outcome scale at 14 days did not significantly differ between the hydroxychloroquine and placebo groups (median [IQR] score, 6 [4-7] vs 6 [4-7]; aOR, 1.02 [95% CI, 0.73 to 1.42]). None of the 12 secondary outcomes were significantly different between groups. At 28 days after randomization, 25 of 241 patients (10.4%) in the hydroxychloroquine group and 25 of 236 (10.6%) in the placebo group had died (absolute difference, -0.2% [95% CI, -5.7% to 5.3%]; aOR, 1.07 [95% CI, 0.54 to 2.09]).

Conclusions and relevance: Among adults hospitalized with respiratory illness from COVID-19, treatment with hydroxychloroquine, compared with placebo, did not significantly improve clinical status at day 14. These findings do not support the use of hydroxychloroquine for treatment of COVID-19 among hospitalized adults.